Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens (ANoPs)

What this Trial Is About

Researchers are investigating the use of the NEO-Match4 test, which utilizes ARTIDIS nanomechanical profiling technology, to predict treatment outcomes and improve clinical decisions in patients suspected of having pancreatic cancer undergoing biopsy. This study aims to determine if the NEO-Match4 test can forecast how patients respond to pre-surgical treatment and how well it detects cancerous pancreatic lesions compared to standard pathology. The study is prospective and single-arm, focusing on adults referred for biopsy of suspicious pancreatic lesions. Participants will undergo standard pancreatic biopsy or surgery as part of their usual care. During these procedures, an extra tissue sample may be taken for analysis with the ARTIDIS ART-1 device, which measures the nanomechanical properties of fresh tissue without direct patient contact. After analysis, the tissue is returned for routine pathology evaluation. The study integrates this testing into normal clinical workflows without altering treatment plans. Throughout the study, clinical data including imaging, pathology, treatments, and outcomes will be collected. Participants will be followed every three months for up to two years to monitor event-free survival, pathological response, progression-free survival, overall survival, and other clinical outcomes. This non-interventional study poses minimal risk and aims to assess how well the nanomechanical measurements correlate with standard diagnostic and treatment results for pancreatic cancer.

Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens